[International clinical practice guidelines and management of rheumatology in Madagascar].
Developed countries issue recommendations regarding healthcare that aren't constantly appropriate for emergent countries. We suggest some remarks concerning rheumatology in Madagascar, taking account of scientific data, medical ethics, equality and equity. We have studied the minimal cost of care of medical conditions found in our hospital department if we were to follow international recommendations for their management. Then, we have estimated treatment expenses as a percentage of the SMIC (Malagasy minimum monthly salary). Out of 517 patients examined yearly, we have found 62.8% osteoarthritis cases, 6.3% rheumatoid arthritis (RA), and 4,2% septic arthritis. Therefore, the first month of treatment for an arthritis of the knee would absorb 147.3% of the SMIC; diagnosis and treatment of a case of septic arthritis would take up 1762.8% of the minimum wage, and a case of RA without biotherapy would require 175%. According to the American College of Rheumatology criteria which are used as a reference, the treatment of an arthritis of the knee would take only 23% of the SMIC. Caring for septic arthritis would demand 57.5% of the SMIC and while it would yield more arguments for diagnosis such as clinical examination, CRP, and Gram coloration on joint liquid aspiration. We can proceed to RA diagnosis with an acceptable security through precise clinical examination, blood cell count, ESR, CRP, rheumatoid factor and radiography. This means 56% of the SMIC. From this 517 patients, our suggestions would reduce the expense by 35,850% of the SMIC per year. The allocation of such funds onto the treatment of complicated forms of rheumatism would be fair. By refining and evaluating these suggestions, we would come up with appropriate recommendations for emergent countries.
Service de rhumatologie, centre hospitalier universitaire JRB, Antananarivo, Madagascar. stephane_ralandison@yahoo.fr
S
S
Ralandison
E
E
Rafalimanana
H
H
Rakotonirainy
R
R
Rabenja
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000191:economics / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use; D002755:Choice Behavior; D017281:Cost of Illness; D019983:Guideline Adherence / Q000191:economics; D017048:Health Care Costs; D006801:Humans; D007391:International Cooperation; D007592:Joint Diseases / Q000175:diagnosis / Q000191:economics / Q000453:epidemiology / Q000628:therapy*; D008270:Madagascar / Q000453:epidemiology; D008727:Methotrexate / Q000191:economics / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012219:Rheumatology / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods
D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D018501:Antirheumatic Agents; D008727:Methotrexate